«

»

Dec 18

Allos reaches SPA contract with FDA for FOLOTYN Phase 3 trial in PTCL Allos Therapeutics.

‘This important study has the potential to support the transformation of our current accelerated acceptance in the U.S. To a complete acceptance and broaden FOLOTYN’s indication to the first-collection setting. The analysis further demonstrates our dedication to the medical community and sufferers to explore the entire potential of FOLOTYN and improve outcomes for sufferers with PTCL.’ Related StoriesSome antibiotics could make MRSA even more harmfulLinkam stages used in the Wolfson Bioimaging Facility at the University of Bristol within the endocytic sorting research of Dr Paul VerkadeScalable production of gene therapy vectors: an interview with Frank UbagsThis Phase 3, randomized, multi-center, worldwide scientific trial will seek to establish the protection and efficacy of sequential FOLOTYN versus observation in sufferers with previously undiagnosed PTCL who have achieved a reply following preliminary treatment with CHOP or CHOP-based chemotherapy.This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an editorially independent information service, is a scheduled system of the Kaiser Family Foundation, a nonpartisan health care policy research corporation unaffiliated with Kaiser Permanente.

Timothy J. Whelan, B.M., B.Ch., Ivo A. Olivotto, M.D., Wendy R. Parulekar, M.D., Ida Ackerman, M.D., Boon H. Chua, M.B., B.S., Ph.D., Abdenour Nabid, M.D., Katherine A. Vallis, M.B., B.S., Ph.D., Julia R. Light, M.D., Pierre Rousseau, M.D., Andre Fortin, M.D., Lori J. Pierce, M.D., Lee Manchul, M.D., Susan Chafe, M.D., Maureen C.